Biohaven initiated with an Outperform at SVB Securities
The Fly

Biohaven initiated with an Outperform at SVB Securities

SVB Securities analyst Marc Goodman initiated coverage of Biohaven (BHVN) with an Outperform rating and $24 price target. The firm likes the fast-follower strategy with the lead asset BHV-7000, which is relatively de-risked as a Kv7 channel activator, and notes Taldefgrobepalpha has a respectable chance of working in spinal muscular atrophy as an adjunctive therapy to standard of care and is currently being assessed in a Phase 3 pivotal trial. Further, Troriluzole remains a wild card with its Phase 3 programs in both obsessive compulsive disorder as well as spinal cerebellar ataxia, while the company’s leadership team has created a great deal of value with the monetization of the migraine franchise to Pfizer (PFE), SVB Securities argues.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BHVN:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App